Primary Therapy With Single Agent Bortezomib as Induction, Maintenance and Re-Induction in Patients With High-Risk Myeloma: Results of the ECOG E2A02 Trial
Leukemia - United Kingdom
doi 10.1038/leu.2010.129
Full Text
Open PDFAbstract
Available in full text
Date
June 10, 2010
Authors
Publisher
Springer Science and Business Media LLC